Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Development of Multimodal Neuroimaging Markers for Neurological Disorders – Part II
Guest editors: Kelvin Wong
Article type: Research Article
Authors: Li, Juna; b; c | Tang, Xiao-Bina; c; * | Wang, Bu-Haib; d; * | Chen, Xue-Meib | Chen, Daa; c | Chai, Leia; c
Affiliations: [a] Department of Nuclear Science & Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing City, Jiangsu Province, China | [b] Radiotherapy Department of Subei People’s Hospital, Yangzhou City, Jiangsu Province, China | [c] Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, China | [d] Cancer Institute of Northern Jiangsu People’s Hospital, Yangzhou City, Jiangsu Province, China
Correspondence: [*] Corresponding author: Xiao-Bin Tang, Ph.D., Department of Nuclear Science & Engineering, Nanjing University of Aeronautics and Astronautics, Nanjing, 210016, P.R. China. Tel.: +86 13601582233; Fax: +86 25 52112906 80407; E-mail: [email protected].
Correspondence: [*] Corresponding author: Bu-Hai Wang, Ph.D., Radiotherapy Department of Subei People’s Hospital, Yangzhou City, Jiangsu Province, China. Tel.: +86 18051062288; E-mail: [email protected].
Abstract: Purpose: The purpose of this study was to compare the dosimetric characteristics for protection of the hippocampus between dual arc VMAT (volumetric modulated arc therapy) and 7 fields intensity-modulated radiation therapy (7F-IMRT) for patients with brain metastases from lung cancer under the whole brain radiotherapy. Methods: Based on ten cases with brain metastases from lung cancer, two types of radiotherapy plans were designed, namely, dual arc VMAT and 7F-IMRT. Provided that the clinical requirements were satisfied, the comparisons of target dose distribution, conformity index (CI), homogeneity index (HI), dose of organs at risk (OARs), monitor units (MU) and treatment time between dual arc VMAT and 7F-IMRT were investigated for their dosimetric difference. Results: Both treatment plans met the requirements of clinical treatments. However, the PTV-HA conformity and homogeneity of dual arc VMAT were superior to those of 7F-IMRT (P < 0.05). As to OARs, the mean maximum doses (Dmax) of hippocampus, eyes and optic nerves in the dual arc VMAT plan were all lower than those in 7F-IMRT plan (P < 0.05), but the result had no statistical significance (P < 0.05) for the maximum dose of lens. Compared with 7F-IMRT, dual arc VMAT reduced the average number of MU by 67% and the average treatment time by 74%. Therefore, treatment time was shortened by dual arc VMAT. Conclusion: With regards to the patients with brain metastases from lung cancer under the whole brain radiotherapy, the PTV-HA conformity and homogeneity of dual arc VMAT were superior to those of 7F-IMRT under the precise of meeting the clinical requirements. In addition, dual arc VMAT remarkably reduced the irradiation dose to OARs (hippocampus, eyes and optic nerves), MU and treatment time, as well, guaranteed patients with better protection.
Keywords: Brain metastases from lung cancer, 7F-IMRT, dual arc VMAT, hippocampus protection, dosimetry parameter comparison
DOI: 10.3233/XST-160561
Journal: Journal of X-Ray Science and Technology, vol. 24, no. 3, pp. 457-466, 2016
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]